Elite US Army units stop taking anti-malarial drug

The top doctor for elite U.S. Army commandos has told troops to immediately stop taking mefloquine, an anti-malaria drug found to cause permanent brain damage in rare cases.

The ban among special operations forces is the latest development in a long-running controversy over mefloquine. The drug was developed by the Army in the 1970s and has been taken by millions of travelers and people in the military over the years. As alternatives were developed, it fell out of favor as the front-line defense against malaria, a mosquito-borne disease that international health officials say kills roughly 600,000 people a year.

The new prohibition follows a July 29 safety announcement by the Food and Drug Administration that it had strengthened warnings about neurologic side effects associated with the drug. The FDA added a boxed warning to the drug label, the most serious kind of warning, saying side effects like dizziness, and ringing in the ears may become permanent.

The drug's other side effects include anxiety, depression and hallucinations—conditions that some military families over the years believe prompted in their loved ones, including killings and suicides.

Quoting the FDA's July safety warning, the Surgeon General's Office of the Army Special Operations Command sent a message to commanders and medical personnel last Friday ordering a halt in prescribing mefloquine for for the approximately 25,000 soldiers, command spokesman Lt. Col. Dave Connolly said.

"What this is is a wake-up call telling troops, 'Look, you've been misinformed,'" said Remington Nevin, a former Army physician and who studies the psychiatric effects of anti-malarial toxicity.

Nevin says the Pentagon should have stopped using the drug years ago, particularly because it confounds diagnosis of PTSD and , two signature health issues of the wars in Iraq and Afghanistan.

Others point out that the drug has been effective in preventing malaria, and many people have preferred it because it is less expensive and has to be taken less often than alternatives.

Mefloquine is still prescribed to the traveling public and to volunteers in the Peace Corps, which also has reduced its use.

The Pentagon says it doesn't have data on the number troops who may have suffered ill effects from the drug. But two days after the FDA announcement, the department began a review "of potential neuropsychological effects on service members who were prescribed mefloquine," said Lt. Col. Cathy Wilkinson, a defense spokeswoman.

The review is expected to be finished in January.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Lawyer: Soldier in Afghan case took malarial drug

Jul 19, 2013

(AP)—The lawyer for the American soldier who killed 16 Afghan civilians says Staff Stg. Robert Bales used a controversial malarial drug linked to paranoia, hallucinations and psychosis while on a previous deployment in ...

FDA investigating PML in patient taking MS drug

Aug 31, 2013

(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug ...

FDA issues warning over-the-counter diarrhea drug

Sep 18, 2012

(AP)—The Food and Drug Administration is warning consumers not to use an over-the-counter drug called Intestinomicina because the anti-diarrhea treatment contains a drug linked to life-threatening injuries.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

3 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

3 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

22 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments